Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Herpes Zoster

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    109 result(s) found for: Herpes Zoster. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2021-005319-30 Sponsor Protocol Number: 217917 Start Date*: 2022-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    20.1 10021881 - Infections and infestations 10030865 Ophthalmic herpes zoster PT
    20.0 10021881 - Infections and infestations 10063491 Herpes zoster oticus PT
    21.1 10021881 - Infections and infestations 10075611 Varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10074297 Herpes zoster cutaneous disseminated PT
    23.1 10021881 - Infections and infestations 10080516 Herpes zoster reactivation PT
    23.1 10021881 - Infections and infestations 10084396 Disseminated varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10072210 Genital herpes zoster PT
    20.1 10021881 - Infections and infestations 10061208 Herpes zoster infection neurological PT
    20.0 10021881 - Infections and infestations 10074259 Herpes zoster meningitis PT
    20.0 10021881 - Infections and infestations 10074248 Herpes zoster meningoencephalitis PT
    20.0 10021881 - Infections and infestations 10074243 Varicella zoster oesophagitis PT
    21.1 10021881 - Infections and infestations 10074254 Varicella zoster pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Ongoing) FI (Ongoing) EE (Ongoing) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004698-86 Sponsor Protocol Number: AcuZoster Effectiveness2006 Start Date*: 2008-07-16
    Sponsor Name:Schmerzambulanz Innenstadt der LMU
    Full Title: Untersuchung der analgetischen Wirkung der AKupunktur bei Patienten mit Herpes zoster im Vergleich mit einer medikamentösen Standardtherapie- Comparison of acupuncture treatment to medical standard...
    Medical condition: Patients suffering from pain due to a herpes zoster infection
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000343-10 Sponsor Protocol Number: V211-020-00 Start Date*: 2007-11-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX™ in Subjects ≥60 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-004020-20 Sponsor Protocol Number: V211-022 Start Date*: 2007-12-10
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of ZOSTAVAX™ in Subjects 50 to 59 Years of Age
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003651-20 Sponsor Protocol Number: V211-017 Start Date*: 2007-06-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (Oka/Merck) in Patients on Chronic/Maintenance Corticosteroids
    Medical condition: Zoster Vaccine
    Disease: Version SOC Term Classification Code Term Level
    8.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) BE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-022248-19 Sponsor Protocol Number: 114825 Start Date*: 2011-01-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: An open, phase II long term extension study to evaluate the immune responses to and safety of GSK Biologicals’ candidate herpes zoster vaccine, (gE/AS01B), at Months 48, 60 and 72 post-vaccination ...
    Medical condition: Evaluation of persistence of immune responses following immunisation of healthy elderly subjects (60-69 and ≥70 years) against Herpes Zoster (HZ)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-020150-34 Sponsor Protocol Number: V212-001-01 Start Date*: 2010-10-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy, and Immunogenicity of V212 in Recipients of Autologous Hematopoiet...
    Medical condition: Incidence of Herpes Zoster in recipients of Autologous HCTs
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) ES (Completed) SE (Completed) CZ (Completed) GB (Completed) LT (Completed) IT (Completed) BE (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023156-89 Sponsor Protocol Number: V212-011 Start Date*: 2011-02-24
    Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc
    Full Title: Ensayo clínico en fase III, aleatorizado y controlado con placebo para estudiar la seguridad y la eficacia de V212 en pacientes adultos con tumor sólido o neoplasia hematológica. A Phase III Rando...
    Medical condition: Incidence of Herpes Zoster in adults with solid tumor or hematologic malignancy Incidencia de Herpes Zoster en pacientes adultos con tumor sólido o neoplasia hematológica.
    Disease: Version SOC Term Classification Code Term Level
    13 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) CZ (Completed) GB (Completed) SK (Completed) AT (Completed) BE (Completed) EE (Completed) LT (Completed) GR (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-002313-11 Sponsor Protocol Number: V212-009-00 Start Date*: 2012-01-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Immunogenicity of V212 in Adult Patients with Autoimmune Disease
    Medical condition: Prevention of herpes zoster in adults with autoimmune disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) BE (Completed) EE (Completed) DK (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-000344-26 Sponsor Protocol Number: V211-012-00 Start Date*: 2007-06-04
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Phase III Double-Blind, Randomized Multicenter Study to Evaluate the Safety, Tolerability and Immunogenicity of ZOSTAVAX administered comcomitantly versus Non-concomitantly with PNEUMOVAX 23 in s...
    Medical condition: herpes zoster, pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-012458-19 Sponsor Protocol Number: ZTV03C Start Date*: 2009-10-15
    Sponsor Name:Sanofi Pasteur MSD S.N.C.
    Full Title: An open-label, randomised, comparative, multicentre study of the immunogenicity and safety of ZOSTAVAX® when administered by intramuscular route or subcutaneous route to subjects ≥50 years of age
    Medical condition: Not applicable as Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN).
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019974 Herpes zoster LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-000965-30 Sponsor Protocol Number: 204486 Start Date*: 2016-02-09
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIIB, non-randomized, open-label, multi-country, multi-centric cross-vaccination study to evaluate the safety of GSK Biologicals' Herpes Zoster subunit (HZ/su) vaccine when administered int...
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10019982 Herpes zoster NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed) CZ (Completed) GB (Completed) DE (Completed) ES (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014268-20 Sponsor Protocol Number: VZV01 Start Date*: 2009-12-24
    Sponsor Name:Erasmus MC
    Full Title: VZV vaccination to prevent herpes zoster after transplantation
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    12.0 10019974 Herpes zoster LLT
    12.0 10036897 Prophylactic vaccination LLT
    12.0 10023438 Kidney transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000373-76 Sponsor Protocol Number: 117177 Start Date*: 2014-01-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomized, double blind multicenter study, to evaluate consistency, immunogenicity, safety and reactogenicity of 3 lots of GSK Biologicals’ herpes zoster HZ/su candidate vaccine when ...
    Medical condition: Herpes Zoster (HZ) and its related complications.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002387-86 Sponsor Protocol Number: 218S18VC Start Date*: 2020-01-08
    Sponsor Name:Pascoe pharmazeutische Präparate GmbH
    Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, 4-ARM PILOT STUDY ON THE USE OF PASCORBIN® AS ADD-ON THERAPY IN PATIENTS WITH ACUTE HERPES ZOSTER
    Medical condition: Acute herpes zoster infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-003035-52 Sponsor Protocol Number: V211-011-00 Start Date*: 2005-10-06
    Sponsor Name:Merck & Co. Inc.
    Full Title: A Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly with Influenza Virus Vaccine (...
    Medical condition: Herpes Zoster
    Disease: Version SOC Term Classification Code Term Level
    8.0 10019974 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000138-20 Sponsor Protocol Number: 115523 Start Date*: 2012-06-07
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomised, observer-blind, placebo-controlled, multicentre, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ herpes zoster gE/AS01B c...
    Medical condition: Vaccination against herpes zoster (HZ) in adult autologous HCT recipients
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FI (Completed) EE (Completed) IT (Completed) CZ (Completed) GB (Completed) FR (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004456-11 Sponsor Protocol Number: 116697 Start Date*: 2012-12-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, randomised, open-label, multicentre, clinical trial to assess the safety and immunogenicity of GSK Biologicals’ HZ/su vaccine when administered intramuscularly according to a 0,2-month...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019974 Herpes zoster PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000367-42 Sponsor Protocol Number: 110390 Start Date*: 2010-07-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Ensayo clínico de vacunación fase III, aleatorizado, observador-ciego, controlado con placebo, multicéntrico para evaluar la eficacia profiláctica, seguridad e inmunogenicidad de la vacuna gE/AS01B...
    Medical condition: Inmunización primaria frente a herpes zoster (HZ) en sujetos igual o mayores de 50 años de edad. La población del estudio está formada por hombres y mujeres no inmunocomprometidos con un intervalo ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) IT (Completed) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015791-94 Sponsor Protocol Number: 113077 Start Date*: 2010-07-12
    Sponsor Name:GlaxoSmithKline SA
    Full Title: Ensayo clínico de vacunación fase III, aleatorizado, observador-ciego, controlado con placebo, multicéntrico para evaluar la eficacia profiláctica, seguridad e inmunogenicidad de la vacuna gE/AS01B...
    Medical condition: Inmunización primaria frente a Herpes Zoster (HZ) en sujetos igual o mayores de 70 años de edad. La población del estudio está formada por hombres y mujeres en un rango de edad de 70 a 79 años e ig...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) EE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:38:17 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA